Ronny Gal
Found 22 people in Arkansas, Florida, Massachusetts and other states
-
+99
-
+98
-
+97
-
-
+95
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
.jpg "BIO Convention Speakers")
.jpg "Speakers")
Ronny - @RonnyGal670
She/Her
Love my wife @stats451
Literally just joined to post art and reblog stuff.
NSFW DNI
רוני גל - @Ronny_gal
סטודנטית לתקשורת ושיווק באוניברסיטת רייכמן👩🏽🎓 מנהלת סושיאל מדיה ודוברת של ח״כ🇮🇱 בעלת פודקאסט ׳פודליטיקה׳🎧
Sponsored by SpokeoPaid Service
Ronny P Gal
S*****@gmail.com — (818) 917-****
***** Secret Harbor Ln, Unit 103, Lake Mary, FL
View full reportSponsored by SpokeoPaid Service
Ronny Gal
Sponsored by PeopleLookerPaid Service
Search for contact info, city & state history, relatives, jobs, education & more
Search public records
Ronny Gal740 - @ronnygal740
38 followers
user1374613756335 - @ronnygal
😍😍❤
101 followers
user580072071056 - @ronnygal2
40 followers
ronny_gal - @ronny_gal
22 followers
Ronnygal - @ronnygal8
189 followers
Ronny&gal🤍 - @_ronny_and_gal_
⛲️🦢🤍🥥☁️🪩🕯️💸🎧🌊
77 followers
Ron gal - @ronny_g22
170 followers
Ronnygal - @ronnygal3
2 followers
ronnygaldona - @ronnygaldona
244 followers
bélico🐓🐓🐓 - @ronnygalan
411 followers
Ron Gallagher911 - @ronnygall3
32 followers
Ronny Galeano416 - @ronnygaleano416
202 followers
Ronny Galeano - @ronnygaleano13
213 followers
Ronny Galvez - @ronnygalvez0
16 followers
Ronny gallardo - @ronny.gallardo1
43 followers
Ronny Gallardo - @ronnygallardo4
Travel lifestyle eat great food 🌎😋
373 followers
Ronny Gale - @ronnygale
13 followers
Ronny Galvis - @ronny_galvis
153 followers
Soccer fan - @ironnygal
Hola mi amigo
8 followers
Ronny Galindez - @ronny.galindez
64 followers
Ronak Gala - @ronnygala
29 followers
RONNY GALA - @ronnygala0
1,608 followers
Ronny Galea - @ronnygalea1
111 followers
Ronny Gal
Novartis
Ronald Gal
Alex Waldron
Neutargeton Therapeutics
Education: Boston ...
Victoria Smith, Ph.D.
Senior IP Search and Analytics Manager
Charmaine Chan
Portfolio Manager, Thrivent Asset ...
Irene Cosmatos
Healthcare Senior analyst/ Software specialist at ...
Zana Dupee
Director of Regulatory Affairs - axogen
Jordan Routhier (O'Brien)
SRA II
Nadin Woergoetter
Head IP Strategy & Analytics - Sandoz ...
Experience: Sandoz International GmbH
Education: University of Pretoria/Universiteit van Pretoria
Eduardo Figueroa
Walgreens
Education: City Colleges of Chicago-Wilbur Wright College
Arthur Pei
Novartis - 领英
Aida Li
Emergent Holdings - Subsidiary of BCBSM
Alexander Liolios
Executive Search & Leadership Advisor ...
Ronny Gal
Sponsored by PeopleLookerPaid Service
Search for Ronny Gal's city and state history
Search address historyThe former Wall Street analyst shaping Novartis’ big-picture strategy
Pharma Voice - Tue, 10 Jun 2025
Aharon (Ronny) Gal, Ph.D.
Novartis - Tue, 19 Jul 2022
Novartis hires seasoned Wall Street analyst Ronny Gal as new M&A czar
Fierce Pharma - Tue, 26 Apr 2022
WSJ News Exclusive | How Novartis’s CEO Learned From His Mistakes and Got Help From an Unlikely Quarter
The Wall Street Journal - Sun, 03 Sep 2023
The exec who decides which drugs Novartis will develop Globes
Israel Business News - Thu, 23 May 2024
Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug
statnews.com - Tue, 04 Jun 2024
Novartis names longtime analyst as top dealmaker amid organizational shakeup
BioPharma Dive - Tue, 26 Apr 2022
Novartis to offload dry-eye drug Xiidra to Bausch + Lomb for $1.75 billion upfront
FirstWord Pharma - Fri, 30 Jun 2023
Novartis Has A New Goal: $2bn Peak Sales Per Product
insights.citeline.com - Tue, 28 Nov 2023
Patient Assistance Programs: Why Pharmaceutical Manufacturers Operate the Biggest U.S. Charities
Drug Channels - Thu, 01 Jun 2017
Biogen's high price for Aduhelm—plus the drug's broad label—could trigger drug pricing reform, analysts say
Fierce Pharma - Tue, 08 Jun 2021
Biosims generating $8B+ in annual savings, and a 'decade of growth' is ahead: analyst
Fierce Pharma - Fri, 02 Jul 2021
Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development
Fierce Pharma - Mon, 06 May 2024
AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst
Fierce Pharma - Mon, 20 May 2019
Eli Lilly promises 40% discount for Innovent's PD-1 in last-ditch bid to shift FDA review to drug pricing
Fierce Pharma - Thu, 10 Feb 2022
UPDATED: UnitedHealth adds to formulary pain for Sanofi, Amgen and Novartis
Fierce Pharma - Thu, 22 Sep 2016
After 'initial shock,' generics supply chain likely to weather COVID-19 blows: analyst
Fierce Pharma - Fri, 27 Mar 2020
Doctors expect enthusiasm for Allergan's high-flying Zeltiq to fade: survey
Fierce Pharma - Tue, 27 Mar 2018
Roche yields to cancer biosim competition by offering 'relevant' discounts: report
Fierce Pharma - Thu, 10 Dec 2020
What do Allergan activists really want? A new CEO to replace Saunders, analyst says
Fierce Pharma - Tue, 05 Mar 2019
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma - Mon, 21 Sep 2020
Novartis confirms 'thousands' of layoffs loom as its global reorganization rolls ahead
Fierce Pharma - Tue, 26 Apr 2022
J&J boasted about defending Remicade from biosims. Now it's under FTC investigation
Fierce Pharma - Tue, 30 Jul 2019
Amgen's Lumakras is set to make a splash, but long-term success might be elusive: analyst
Fierce Pharma - Wed, 26 May 2021
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma - Tue, 22 May 2018
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Fierce Pharma - Fri, 05 Mar 2021
Viatris, Organon could merge given similar business models, but one of them already seems more credible: analyst
Fierce Pharma - Tue, 11 May 2021
Biogen's blockbuster Tysabri loses a key patent in Europe, adding to company's worries: analyst
Fierce Pharma - Thu, 15 Jul 2021
Mylan decimates the list price of its Copaxone copy. But why?
Fierce Pharma - Mon, 09 Jul 2018
AbbVie's aesthetics products bounce back, smoothing investors' pandemic-induced worry lines: report
Fierce Pharma - Mon, 24 May 2021
Cigna's $500 gift to psoriasis patients who switch to Eli Lilly's Taltz is 'rehearsal' for Humira biosimilars: analyst
Fierce Pharma - Tue, 06 Apr 2021
Can Allergan's spruced-up aesthetics lineup shake off 'meh' Kybella growth?
Fierce Pharma - Mon, 10 Jul 2017
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
Fierce Pharma - Fri, 04 Jan 2019
AbbVie's Imbruvica patent win sets up solid growth path after Humira's decline: analyst
Fierce Pharma - Tue, 31 Aug 2021
Payers keep squeezing MS drugmakers--and they may just take their tactics elsewhere
Fierce Pharma - Wed, 22 Jun 2016
Humira biosimilars catch fire in Europe and could take half the market in a year: report
Fierce Pharma - Fri, 25 Jan 2019
Glaxo serves up 20% payer discounts on Advair to soften generic blow
Fierce Pharma - Mon, 06 Mar 2017
AbbVie offers up 80% Humira discount in EU tender market to hold off biosimilars: report
Fierce Pharma - Wed, 31 Oct 2018
As competition heats up, U.S. prices for Remicade and biosims slip: analyst
Fierce Pharma - Tue, 11 Dec 2018
Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
Fierce Pharma - Fri, 14 Jul 2017
AbbVie Sees 80% Discounts in Nordic Market With New Humira Biosimilars
Regulatory Affairs Professionals Society | RAPS - Fri, 02 Nov 2018
Optum, Aetna, Cigna and Prime Therapeutics Join the PBM Formulary Exclusion Party
Drug Channels - Wed, 02 Dec 2015
GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst
Fierce Pharma - Mon, 31 Jul 2017
Biogen stands to lose billions in Tecfidera sales next year, analyst says after new court ruling
Fierce Pharma - Fri, 18 Sep 2020
'Teva Overpaid for Cephalon by $880m'
Haaretz - Fri, 06 May 2011
"We want to be a bridge between Israel and the world in biomed" Globes
Israel Business News - Thu, 23 May 2024
Pill That Eliminates the Period Gets Mixed Reviews (Published 2007)
The New York Times - Fri, 20 Apr 2007
Ronny Gal - @ronnygal100
0 followers
Ronny Gal - @wowwow16
0 followers
Rhonda Stallings - @ronnygal
73 followers
Ronny Gal
Lives in Be'er Ya`aqov
4 followers
Aharon (Ronny) Gal, Ph.D. | Novartis
https://www.novartis.com/about/executive-committee/aharon-ronny-gal-…
Novartis hires Wall Street analyst Ronny Gal as new M&A czar
Longtime Sanford Bernstein analyst Ronny Gal, Ph.D., will join Novartis as chief strategy and growth officer, effective no later than Aug. 1, Novartis said Tuesday.
Novartis names longtime analyst as top dealmaker amid …
Novartis on Tuesday named Ronny Gal, a longtime analyst with advisory firm Bernstein, as its chief strategy and growth officer, the latest move in an organizational …
Ronny Gal, Novartis AG: Profile and Biography - Bloomberg Markets
Ronny Gal is Chief Strategy & Growth Officer at Novartis AG. See Ronny Gal's compensation, career history, education, & memberships.
Novartis ernennt Aharon (Ronny) Gal zum Chief Strategy ... - Börse
Basel (awp) - Der Pharmakonzern Novartis hat Aharon (Ronny) Gal per 1. August 2022 zum Chief Strategy & Growth Officer ernannt. Er wird die neu geschaffene …
Aharon (Ronny) Gal, Ph.D. | Novartis
Usage Rights & Restrictions. This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes. Download (IMAGE 277.13 KB) Novartis. Working together. …
Ronny Gal - Biography
Presently, Ronny Gal occupies the position of Senior Analyst at Sanford C. Bernstein & Co. LLC. He is also Chief Strategy & Growth Officer at Novartis AG. Dr. Gal previously held the …
The exec who decides which drugs Novartis will develop - Globes
Dr. Ronny Gal, Novartis's Chief Strategy and Growth Officer: Our aim is that half our innovative products should come from outside the company.
Aharon Gal: Positions, Relations and Network - MarketScreener
Aharon Gal is currently the Chief Strategy & Growth Officer at Novartis AG since 2022. Bernstein & Co. LLC since 2004. Life Sciences, Inc. from 2003 to 2004. Dr. Gal …
How Novartis’s CEO Learned From His Mistakes and Got Help From …
How Novartis’s CEO Learned From His Mistakes and Got Help From an Unlikely Quarter. After some deals and drug launches disappointed, Vas Narasimhan heard from …
Novartis hires seasoned Wall Street analyst Ronny Gal as new M&A …
Now, he has found that leader in the form of a high-profile Wall Street analyst. Longtime Sanford Bernstein analyst Ronny Gal, Ph.D., will join Novartis as chief strategy and growth …
How Novartis's CEO Learned From Mistakes and Got Help From an …
Gal, a hard-charging Israeli-American who was an outspoken Wall Street analyst, never worked in pharma before a year ago. Now he—and his no-holds-barred reports—are …
Aharon Gal - Chief Strategy & Growth Officer at Novartis - The Org
Dr. Gal leads the newly created Strategy & Growth function that combines corporate strategy, R&D portfolio strategy and business development. Dr. Gal joined Novartis from Sanford …
Novartis names longtime analyst as top dealmaker amid …
Novartis on Tuesday named Ronny Gal, a longtime analyst with advisory firm Bernstein, as its chief strategy and growth officer, the latest move in an organizational shakeup the Swiss …
Novartis struggling to win payer coverage for $2.1M gene therapy ...
Ronny Gal and his colleagues at Bernstein collected early coverage decisions on Zolgensma from 11 payers and found them to be “surprisingly restricted,” the firm said in a …
Ronny Gal’s Profile | Globes, הצוללת Journalist | Muck Rack
By Yaron Daniely, Ronny Gal, Gali Weinreb | הצוללת At the beginning of 2023, Dr. Ronny (Aharon) Gal, one of the best known and longest-serving analysts in the …
In a surprise move, Novartis CEO Vas Narasimhan recruits top …
Editor & Founder. After a long run observing Novartis and the rest of the Big Pharma world as a top analyst, Bernstein’s Ronny Gal will now move into ….
Ronny Gal: Analyst wird Strategie-Chef von Novartis
Der Novartis-Konzernchef beruft per 1. August einen Pharma-Analysten zum Strategiechef. Und zwar nicht irgendeinen, sondern Ronny Gal, langjähriger Analyst von …
TipRanks | Stock Market Research, News and Analyst Forecasts
TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.com
Ronny Gal | WallStreetZen
Ronny Gal's Stock Forecasts. Sectors: Healthcare. Industries: Biotechnology. Follow Analyst. Analyst Ranking. Top 48%. #2221 out of 4614 analysts.